BriaCell Therapeutics Corp. Common Shares (BCTX)
Stock · NASDAQ · Health Care
$3.43as of 10/16/2026
Price chart
Active signals
BCTX Signal Track Record
How signals performed across all stocks →What BCTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -6.5% | 32% | September 17, 2026 |
| Bollinger Band Breakout | 23 | -10.3% | 39% | September 17, 2026 |
| Bollinger Band BreakdownActive now | 21 | -9.3% | 33% | May 15, 2026 |
| 200-Day Moving Average TouchActive now | 4 | +6.9% | 75% | September 30, 2026 |
| Any 20-session window (baseline) | -5.0% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BCTX
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- briacell.com/
Fundamentals
- 1-day range
- $3.39$3.91
- Market cap
- $30.01M
- P/E (trailing)
- —
- P/E (forward)
- -8.72
- EPS (trailing)
- $-17.14
- Dividend yield
- —
- Beta
- 1.04
- Avg. volume
- 266.6K
- Dividend pay date
- January 2, 2020
BriaCell Therapeutics Corp. Common Shares Competitors
Chosen by industry and closest market cap.
- BCTXBriaCell Therapeutics Corp. Common Shares$3.4▼ 9.81%Market cap $30.01MP/E —$3.68$20.4
- ACTUActuate Therapeutics Inc. Common stock$0.605▲ 21.00%Market cap $29.43MP/E —$0.41$8.27
- UPCUniverse Pharmaceuticals Inc. Class A Ordinary Shares$3.93▼ 5.30%Market cap $31.35MP/E —$2$17.96
- QUCYQuantum Cyber N.V. Ordinary Shares$1.06▼ 2.75%Market cap $31.42MP/E —$0.3$4.93
- MIRAMIRA Pharmaceuticals Inc. Common Stock$0.632▼ 3.95%Market cap $28.50MP/E —$0.6$2.45
- GRCEGrace Therapeutics Inc. Common Stock$1.89▼ 3.08%Market cap $28.44MP/E —$1.79$5.18
- LITSLite Strategy Inc. Common Stock$1.15▼ 4.17%Market cap $31.61MP/E —$0.6888$2.26
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BCTX BriaCell Therapeutics Corp. Common Shares | $30.01M | — | $3.4 | ▼ 9.81% | $3.68$20.4 |
| ACTU Actuate Therapeutics Inc. Common stock | $29.43M | — | $0.605 | ▲ 21.00% | $0.41$8.27 |
| UPC Universe Pharmaceuticals Inc. Class A Ordinary Shares | $31.35M | — | $3.93 | ▼ 5.30% | $2$17.96 |
| QUCY Quantum Cyber N.V. Ordinary Shares | $31.42M | — | $1.06 | ▼ 2.75% | $0.3$4.93 |
| MIRA MIRA Pharmaceuticals Inc. Common Stock | $28.50M | — | $0.632 | ▼ 3.95% | $0.6$2.45 |
| GRCE Grace Therapeutics Inc. Common Stock | $28.44M | — | $1.89 | ▼ 3.08% | $1.79$5.18 |
| LITS Lite Strategy Inc. Common Stock | $31.61M | — | $1.15 | ▼ 4.17% | $0.6888$2.26 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Institutional Ownership
March 31, 2026
- Total shares held
- 386.8K
- Total value held
- $1.62M
- Institutional holders
- 16
- Unknown216.8K
- Unknown73.9K
- Unknown65.0K
- Unknown15.0K
- Unknown11.5K
- Unknown3.0K
- Unknown802
- Unknown455
- Unknown100
- Unknown100
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
BriaCell to Present Four Posters at SITC 2026 Annual Meeting
BriaCell Therapeutics announced that it and its partner BriaPro will present four posters at the 2026 Society for Immunotherapy of Cancer (SITC) Annual Meeting. This event provides a platform to share clinical data, which is often a key catalyst for biotechnology companies. The stock is currently trading near its 52-week low, making new scientific disclosures particularly relevant for investors tracking the firm's progress.
BriaCell to Present Four Posters at SITC 2026 Annual Meeting. BriaCell Therapeutics announced that it and its partner BriaPro will present four posters at the 2026 Society for Immunotherapy of Cancer (SITC) Annual Meeting. This event provides a platform to share clinical data, which is often a key catalyst for biotechnology companies. The stock is currently trading near its 52-week low, making new scientific disclosures particularly relevant for investors tracking the firm's progress.